drugset / Trial / NCT02206503
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the efficacy of the addiction of Cyclophosphamide to Revlimid-low dose dexamethasone (Rd) in relapsed/refractory Multiple Myeloma patients, who experienced a biochemical progression, without CRAB, during Rd treatment.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-04
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |